(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer

Author:

Rosas Juan C.12ORCID,Aguado‐Barrera Miguel E.3ORCID,Azria David4,Briers Erik5,Elliott Rebecca6,Farcy‐Jacquet Marie‐Pierre7,Giraldo Alexandra8,Gutiérrez‐Enríquez Sara9ORCID,Rancati Tiziana10,Rattay Tim11,Reyes Victoria8,Rosenstein Barry12,De Ruysscher Dirk1314,Sperk Elena15,Stobart Hilary16,Talbot Christopher11,Vega Ana317,Taboada‐Valladares Begoña318,Veldeman Liv1920,Ward Tim21,Webb Adam11,West Catharine6,Chang‐Claude Jenny122,Seibold Petra1,

Affiliation:

1. Division of Cancer Epidemiology German Cancer Research Center (DKFZ) Heidelberg Germany

2. Institute for Medical Information Processing, Biometry and Epidemiology Ludwig‐Maximilians University Munich Germany

3. Instituto de Investigación Sanitaria de Santiago de Compostela Fundación Pública Galega de Medicina Xenómica (FPGMX) Santiago de Compostela Spain

4. University of Montpellier INSERM U1194 IRCM, Institut du Cancer Montpellier (ICM) Montpellier France

5. Patient advocate Hasselt Belgium

6. University of Manchester Manchester UK

7. Federation Universitaire d'Oncologie Radiothérapie d'Occitanie Méditerranée Institut du Cancer Du Gard (ICG), CHU Carémeau Nîmes France

8. Radiation Oncology Department Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus Barcelona Spain

9. Hereditary Cancer Genetics Group Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus Barcelona Spain

10. Istituto Nazionale dei Tumori Data Science Unit Milan Italy

11. University of Leicester Leicester UK

12. Icahn School of Medicine at Mount Sinai New York New York USA

13. Maastro Clinic Maastricht The Netherlands

14. KU Leuven Leuven Belgium

15. Universitätsmedizin Mannheim, Mannheim Cancer Center, Medical Faculty Mannheim Heidelberg University Mannheim Germany

16. Independent Cancer Patients' Voice London UK

17. Biomedical Network on Rare Diseases (CIBERER) Seville Spain

18. Department of Radiation Oncology Complexo Hospitalario Universitario de Santiago, SERGAS Santiago de Compostela Spain

19. Ghent University Hospital Ghent Belgium

20. Ghent University Ghent Belgium

21. NCRI CTRad Consumer London UK

22. University Cancer Center Hamburg University Medical Center Hamburg‐Eppendorf Hamburg Germany

Abstract

AbstractFatigue is common in breast‐cancer survivors. Our study assessed fatigue longitudinally in breast cancer patients receiving adjuvant radiotherapy (RT) and aimed to identify risk factors associated with long‐term fatigue and underlying fatigue trajectories. Fatigue was measured in a prospective multicenter cohort (REQUITE) using the Multidimensional Fatigue Inventory (MFI‐20) and analyzed using mixed models. Multivariable logistic models identified factors associated with fatigue dimensions at 2 years post‐RT and latent class growth analysis identified individual fatigue trajectories. A total of 1443, 1302, 1203 and 1098 patients completed the MFI‐20 at baseline, end of RT, after 1 and 2 years. Overall, levels of fatigue significantly increased from baseline to end of RT for all fatigue dimensions (P < .05) and returned to baseline levels after 2 years. A quarter of patients were assigned to latent trajectory high (23.7%) and moderate (24.8%) fatigue classes, while 46.3% and 5.2% to the low and decreasing fatigue classes, respectively. Factors associated with multiple fatigue dimensions at 2 years include age, BMI, global health status, insomnia, pain, dyspnea and depression. Fatigue present at baseline was consistently associated with all five MFI‐20 fatigue dimensions (ORGeneralFatigue = 3.81, P < .001). From latent trajectory analysis, patients with a combination of factors such as pain, insomnia, depression, younger age and endocrine therapy had a particularly high risk of developing early and persistent high fatigue years after treatment. Our results confirmed the multidimensional nature of fatigue and will help clinicians identify breast cancer patients at higher risk of having persistent/late fatigue so that tailored interventions can be delivered.

Funder

Instituto de Salud Carlos III

Fundación Mutua Madrileña

Fundación Científica Asociación Española Contra el Cáncer

Manchester Biomedical Research Centre

Cancer Research UK

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3